TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04199884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active IU-focused Psychoeducation Intervention
Description: This paradigm was an IU-focused psychoeducation intervention wherein participants were provided psychoeducation about the nature of IU and anxiety, given strategies to cope with fear of uncertainty, and provided examples and information as to how they can expose themselves to uncertainty.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health-focused Psychoeducation Intervention
Description: This intervention is a health-focused psychoeducation intervention wherein participants learn ways to engage in healthy behaviors, such as getting adequate sleep, eating healthier, and exercising regularly.
Study: NCT00204022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Azathioprine
Study: NCT00794417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Administered in combination with the other two interventions via intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Administered in combination with the other two interventions via intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Administered in combination with the other two interventions via intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Administered in combination with the other two interventions via intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered in combination with the other two interventions via intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered in combination with the other two interventions via intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered in combination with the other two interventions via intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered in combination with the other two interventions via intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered in combination with the other two interventions via intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered in combination with the other two interventions via intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered in combination with the other two interventions via intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered in combination with the other two interventions via intravenous infusion.
Study: NCT04825717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition and fluid plans prepared using calorimetry-based measurements.
Description: Nutrition and fluid plans prepared using calorimetry-based measurements.
Study: NCT05577806

Intervention type: DRUG
Intervention: Dydrogesterone
Description: progestin primed ovarian stimulation
Study: NCT03100890

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative training (hospital)
Description: Preoperative hospital training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative training (home)
Description: Preoperative in-home training
Study: NCT03353298

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol 300 mg
Description: Allopurinol oral tablets 300 mg given to participants once daily for 9 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo oral tablets given to participants once daily for 9 months
Study: NCT02430415

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laryngoscope-assisted lightwand intubation
Description: laryngoscope-assisted lightwand intubation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laryngoscope-assisted lightwand intubation
Description: laryngoscope-assisted lightwand intubation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: traditional lightwand intubation
Description: traditional lightwand intubation
Study: NCT02430415

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: traditional lightwand intubation
Description: traditional lightwand intubation
Study: NCT01841216

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lower Body Exercises with and without resistance
Description: lower body exercises with and without resistance designed to activate the gluteal/hip musculature

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lower Body Exercises with and without resistance
Description: lower body exercises with and without resistance designed to activate the gluteal/hip musculature
Study: NCT02751827

Intervention type: OTHER
Intervention: Blood sample
Description: One blood sample before treatment initiation (Cycle 1 Day predose) for pharmacogenomics~One blood sample at the end of the firth month of treatment (postdose) for pharmacokinetic
Study: NCT03977259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individually targeted fortification
Description: Abbott liquid protein and/or medium chain triglyceride are added routinely to ensure that the base milk has protein 1 g/dL and calories 67/dL.
Study: NCT01537003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Promogran
Description: Promogran is a collagen/ORC dressing which modulates the wound environment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Promogran
Description: Promogran is a collagen/ORC dressing which modulates the wound environment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coban 2 layer
Description: Compression bandage

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coban 2 layer
Description: Compression bandage
Study: NCT02616835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: theta-burst TMS
Description: This protocol involves short periods of pulse delivery in combination with long periods of silent intervals.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham theta-burst TMS
Description: This protocol delivers theta-burst pulses from a sham device (i.e. at same speed and timeframe but without the magnetic output)
Study: NCT03920215

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OC-01 Low Dose, 0.12 mg/mL
Description: OC-01 (varenicline) nasal spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OC-01 Mid Dose, 0.6 mg/mL
Description: OC-01 (varenicline) nasal spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OC-01 High Dose, 1.2 mg/mL
Description: OC-01 (varenicline) nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle) nasal spray
Description: Placebo (vehicle) nasal spray
Study: NCT02000817

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Otelixizumab
Description: Otelixizumab is available at unit dose strength of 5 milligram/mL provided as 1 mL solution per vial to be diluted to 0.1 mg/mL in 0.9% sodium chloride. The 0.1 mg/mL solution is to be administered by intravenous infusion using a syringe pump and an in-line 0.2 micron filter by study personnel following specified regimens

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Otelixizumab
Description: Otelixizumab is available at unit dose strength of 5 milligram/mL provided as 1 mL solution per vial to be diluted to 0.1 mg/mL in 0.9% sodium chloride. The 0.1 mg/mL solution is to be administered by intravenous infusion using a syringe pump and an in-line 0.2 micron filter by study personnel following specified regimens

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Otelixizumab
Description: Otelixizumab is available at unit dose strength of 5 milligram/mL provided as 1 mL solution per vial to be diluted to 0.1 mg/mL in 0.9% sodium chloride. The 0.1 mg/mL solution is to be administered by intravenous infusion using a syringe pump and an in-line 0.2 micron filter by study personnel following specified regimens

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Otelixizumab
Description: Otelixizumab is available at unit dose strength of 5 milligram/mL provided as 1 mL solution per vial to be diluted to 0.1 mg/mL in 0.9% sodium chloride. The 0.1 mg/mL solution is to be administered by intravenous infusion using a syringe pump and an in-line 0.2 micron filter by study personnel following specified regimens

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is available 0.9% w/v sodium chloride
Study: NCT03393377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluvastatin 10 mg and valsartan 20 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00588809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: Given PO
Study: NCT02914951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy
Description: CBT is a behavioral intervention that consists of 12 60- to 90-minute-long weekly sessions. A modified, principles-based form of CBT will be used in this study to reduce complexity of activities during therapy sessions while retaining all key elements and principles of CBT.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI)
Description: Functional magnetic resonance imaging (fMRI). There will be two fMRI visits, 60 to 90 minute each, one before and the other after CBT. fMRI is a technique that uses magnetism to measure activity of the brain as participants perform simple tasks such as pressing the button in response to pictures. During this study, children will be asked to look at pictures of objects and press or not press the button in response to specific instruction. Participants will also look at pictures of faces and light-point displays depicted biological motion. fMRI is used as an outcome measure to explore if change in irritability is associated with change in brain responses to these tasks during fMRI.
Study: NCT02201173

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Locomotor Training
Description: Progressive retraining in functional skills including balance, transfers, activities of daily living and ambulation. Compliance to eliminate or minimize lower limb orthotics is also expected to optimize sensory input to the spinal cord and promote optimal recovery. Intensive therapy occurs in all three environments 5 times/ week for 90 minutes
Study: NCT01038648

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 100mg/day
Study: NCT04600284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2101 + AD-2102
Description: AD-2101 16/5mg + AD-2102 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2101 + AD-2102
Description: AD-2101 16/5mg + AD-2102 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2101 + AD-2102
Description: AD-2101 16/5mg + AD-2102 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2101 + AD-2102
Description: AD-2101 16/5mg + AD-2102 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2101 + AD-2102
Description: AD-2101 16/5mg + AD-2102 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2101 + AD-2102
Description: AD-2101 16/5mg + AD-2102 25mg
Study: NCT03017001

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CHO (carbohydrate)
Description: Patients in this group received a preoperative fast for solids for 6h and a drink containing water plus 12.5% maltodextrine (carbohydrate) 2h before anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous w-3 PUFA
Description: Patients in this groups received during the operation (intraoperative) a dose of intravenous w3-PUFA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHO (carbohydrate) plus intravenous w3-PUFA
Description: Patients in this group received a preoperative fast for solids for 6h and a drink containing water plus 12.5% maltodextrine (carbohydrate) 2h before anesthesia, plus an intravenous dose of w3-PUFA intraoperatively
Study: NCT02656056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food: (Q-Can Plus fermented soybean beverage)
Description: Fermented soybean beverage. Dose is 8 oz, twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food: (Q-Can Plus fermented soybean beverage)
Description: Fermented soybean beverage. Dose is 8 oz, twice daily.
Study: NCT02089204

Intervention type: RADIATION
Intervention: FMISO-PET/CT
Description: Fluorine-18-labeled fluoromisonidazole PET/CT-guided dose escalation chemoradiotherapy (group C). Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation treatment arms. Patients received concurrent and adjuvant chemotherapy.

Intervention type: RADIATION
Intervention: FDG-PET/CT
Description: 18F-FDG PET/CT -guided dose escalation chemoradiotherapy. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation treatment arms. Patients received concurrent and adjuvant chemotherapy.

Intervention type: RADIATION
Intervention: contrast-enhanced CT
Description: contrast-enhanced CT -guided dose escalation chemoradiotherapy. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation treatment arms. Patients received concurrent and adjuvant chemotherapy

Intervention type: RADIATION
Intervention: contrast-enhanced CT
Description: contrast-enhanced CT -guided dose escalation chemoradiotherapy. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation treatment arms. Patients received concurrent and adjuvant chemotherapy
Study: NCT01038648

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: life style modification at base line
Description: Advice on physical activity, diet and drug adherence.
Study: NCT03621696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: -100 mg/m\^2 intravenous push bolus (IVPB)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: -100 mg/m\^2 intravenous push bolus (IVPB)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy
Description: -IMRT or IMPT can be used
Study: NCT02089204

Intervention type: RADIATION
Intervention: contrast-enhanced CT
Description: contrast-enhanced CT -guided dose escalation chemoradiotherapy. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation treatment arms. Patients received concurrent and adjuvant chemotherapy
Study: NCT02196922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telehealth Self Management (TSM)
Description: Experimental: Telehealth Self Management (TSM) TSM is defined as a weekly clinical telehealth visit and self-monitoring of daily vital signs utilizing a subject monitor which connects from the subject's residence, via a standard telephone line to the provider station.
Study: NCT03621696

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy
Description: -IMRT or IMPT can be used
Study: NCT01613664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tisseel
Description: The product will be given as a 2 mL bottle per patient, which will be spread along the staple line. If necessary, a second bottle of 2 mL is used. The precautions for use are described in the user manual.
Study: NCT00242580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin photodynamic therapy
Description: After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, verteporfin was activated by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaptanib
Description: Pegaptanib sodium 0.3 mg administered by intravitreal injection.
Study: NCT01613664

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no tisseel
Description: the surgeon does not applied tissucol during the surgery
Study: NCT02492841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate
Description: Mineral trioxide aggregate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide
Description: Classic calcium hydroxide root canal repair material. Inorganic compound (CA(OH)2. It is the gold standard direct pulp cupping material.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: Biodentine (trademark). Septodont. Biodentine root canal repair material. A predose capsule plus five drops of calcium chloride solution.
Study: NCT02601274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theliatinib
Description: Theliatinib is a tablet in the form of 25 mg ,10mg and 100 mg,oral,once daily
Study: NCT00946049

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vicryl Plus
Study: NCT02196922

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patients receiving standard of care experience typical chronic care management received by Medicare patients.
Study: NCT03700229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib intravenously 1.3mg/m2 d1,4,8,11 for 4 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: rituximab intravenously 500 mg for one dose
Study: NCT02008617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 30mL of Bupivicaine 0.20% with epinephrine 1:300,000
Study: NCT00946049

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vicryl
Study: NCT03413384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Description: 1 g ceftriaxone per day for Day 1, 3, and 5 per cycle on a 2 weekly cycle

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo per day for Day 1, 3, and 5 per cycle on a 2 weekly cycle
Study: NCT02246868

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Optivate® (Human Coagulation Factor VIII)
Study: NCT03581188

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient-led surveillance
Description: Usual care plus reminders, ASICA instructional videos, a mobile dermatoscope, an app that facilitates store-and-forward teledermatology, and fast-tracked unscheduled clinic visits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinician-led surveillance
Description: Usual care (scheduled clinician visits)
Study: NCT03159286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abstainer
Description: Participants view social networking site profiles with alcohol content referencing abstaining from alcohol use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abstainer + User
Description: Participants view social networking site profiles with alcohol content referencing abstaining from alcohol use and using alcohol.
Study: NCT02008617

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Preservative free normal saline
Description: Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline
Study: NCT01987414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: occupational therapy task-oriented approach
Description: It is a standard treatment in occupational therapy for persons post-stroke or other neurological conditions. It is an approach that emphasizes client-centered, goal-directed, and functional training for restoration of life roles.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: occupational therapy task-oriented approach
Description: It is a standard treatment in occupational therapy for persons post-stroke or other neurological conditions. It is an approach that emphasizes client-centered, goal-directed, and functional training for restoration of life roles.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forearm rotation orthosis
Description: The forearm rotation orthosis is made of Latex-free material and is a custom-molded orthosis designed to assist forearm rotation without limiting functional elbow flexion and extension.
Study: NCT03159286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Participants view social networking site profiles with no alcohol content.
Study: NCT04399265

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Trehalose
Description: A disaccharide sugar usually used as food preservative, but for this study it is given at a higher dose

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltose
Description: Maltose power
Study: NCT06191679

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid for Education and Support about Cancer Treatment (DECIDES Intervention)
Description: DECIDES is a developmentally appropriate, engaging, and interactive web-based decision support intervention for AYA diagnosed with cancer (and their caregivers) that includes components written for low health literacy. Components include:~* Education on cancer and cancer treatments, including clinical trials~* An exercise to identify perceived barriers and benefits to treatment options~* An exercise to clarify personal goals for treatment that align with life goals~* Resources to support communication with the oncology health care team
Study: NCT01987414

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No treatment
Description: Participants will maintain their daily routines during the no treatment period.
Study: NCT01515371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA
Description: Subject to receive one injection of either 2.5U, 5U or 7.4U of IncobotulinumtoxinA.~For three dose stages: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), reconstitution volume 8 ml, 4 ml and 2.7 ml per 50U vial, respectively, resulting in a concentration of 6.25 U/ml, 12.5 U/ml and 18.5 U/ml. Injection volume is 0.4 ml for all three dose stages. Mode of administration: unilateral soft palate injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: For three dose stages: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), reconstitution volume 8 ml, 4 ml and 2.7 ml per vial, respectively. Injection volume is 0.4 ml for all three dose stages. Mode of administration: unilateral soft palate injection.
Study: NCT00242580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide
Description: Triamcinolone acetonide administered by intravitreal injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide
Description: Triamcinolone acetonide administered by intravitreal injection.